Kimberly Allman, MSN, CNP Cleveland Clinic Taussig Cancer Institute discusses Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint Inhibitor-Refractory Metastatic Renal Cell Carcinoma at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.
Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint Inhibitor-Refractory Metastatic Renal Cell Carcinoma
By Editor